Reports
Sale
Europe Viral Vector Manufacturing Market Size, Share, Growth: By Type: Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, Retroviral Vectors, Others; By Application: Gene Therapy, Cell Therapy, Vaccines; By Therapeutic Area: Oncological Disorders, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Europe Viral Vector Manufacturing Market Outlook
The global viral vector manufacturing market size was valued at USD 2.6 billion in 2023, with Europe holding a significant market share. The market is driven by advancements in gene therapy and vaccine development. It is expected to grow at a CAGR of 19.74% during the forecast period of 2024-2032, with the values likely to attain USD 13.5 billion by 2032.
Key Takeaways
- According to the Alliance for Regenerative Medicine, around 358 gene therapy trials were reported in Europe in 2023, with the total investment in gene therapy estimated to be USD 1.2 billion in the year. The rising focus on gene therapy to treat various diseases is expected to directly impact the market demand.
- The key market players are actively investing in the capacity expansion of their production facilities which is likely to boost Europe viral vector manufacturing market share in coming years. In June 2023, Yposkesi, the viral vector manufacturing subsidiary of SK pharmteco’s (a CDMO) in France, completed its second facility for the manufacture of cell and gene therapies.
- A major market trend is the rise in strategic partnerships between the leading biotechnology companies and contract development and manufacturing organizations (CDMOs). In December 2023, Oxford Biomedica entered into an agreement to acquire ABL Europe S.A.S. from Institut Mérieux SA.
Europe Viral Vector Manufacturing Market Analysis
Viral vectors are increasingly used in research settings to deliver genetic material into cells. They are considered the most effective means to transfer genes, to modify a certain cell type or tissue and manipulate them to produce therapeutic proteins. Besides their application in gene therapy and vaccine development, viral vectors are also being explored in other medical fields such as regenerative medicine, immuno-oncology, and neurological disorders. To accommodate these emerging applications, many pharmaceutical and biotechnology companies are investing to expand their production capabilities, which is expected to significantly contribute to the Europe viral vector manufacturing market growth.
The market is witnessing increased demand for viral vectors, which can be attributed to the growing impetus on gene therapy to treat various diseases. According to the Alliance for Regenerative Medicine (an international advocacy organization working to advance safe and effective regenerative cell therapies), around 358 gene therapy trials were reported in Europe in 2023, with the total investment in gene therapy estimated to be USD 1.2 billion in the year. Thus, to meet the growing demand for gene therapy and keep up with the rising advancements, companies involved in viral vector manufacturing are continuously working towards improving production efficiency and capacity, which is likely to elevate the Europe viral vector manufacturing market value.
In June 2023, the global contract development and manufacturing organization (CDMO) SK pharmteco’s Yposkesi, the viral vector manufacturing subsidiary in France announced the completion of its second facility for the manufacture of cell and gene therapies, particularly specialized for adeno-associated virus (AAV) and lentiviral vectors (LVs) production. Located in the Genopole Campus, the facility is designed with the current (Good Manufacturing Practices) GMP guidelines of Europe and the United States and spans an area of 5,000 square meters. Following the construction of the second cell and gene therapy production, Yposkesi now functions in an area of 10,000 square meters together with the first bioproduction site. The facility will amplify production capacity and help expand the company’s presence in the anti-cancer and immune cell therapy market. Such increased investments to boost production capacity by the major market players is anticipated to augment market share in the coming year.
One of the major Europe viral vector manufacturing market trends is the increased merger and acquisition activities among the leading companies to establish their presence in international markets. In December 2023, Oxford Biomedica (gene and cell therapy biotech company) entered into an agreement to acquire ABL Europe S.A.S. (a pure-play European CDMO) from Institut Mérieux SA (a French holding biotechnology company). The transaction, completed in January 2024, will provide Oxford Biomedica with multi-viral vector CDMO capabilities across multiple sites in the European Union, United States, and United Kingdom as well as offer new facilities in France to improve service for its customers by addressing the demand for process development. Additionally, the acquisition will strengthen the company’s position as the leading cell and gene therapy CDMO. The rise in such strategic partnerships is poised to bolster market growth in the forecast period.
Europe Viral Vector Manufacturing Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Type | Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, Retroviral Vectors, Others |
| Application | Gene Therapy, Cell Therapy, Vaccines |
| Therapeutic Area | Oncological Disorders, Neurological Disorders, Metabolic Disorders, Immunological Disorders, Others |
| End User | Research Organizations, Biotech and Pharmaceutical Companies, Others |
| Country | United Kingdom, Germany, France, Italy, Others |
Europe Viral Vector Manufacturing Market: Competitor Landscape
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Lonza Group AG
- Merck KGaA
- Oxford Biomedica
- Novartis AG
- Sartorius AG
- SIRON Biotech
- PlasmidFactory GmbH
- Kaneka Eurogentec S.A.
- Advanced BioScience Laboratories, Inc.
- F. Hoffmann-La Roche AG
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Application |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Europe Viral Vector Manufacturing Market Overview
3.1 Europe Viral Vector Manufacturing Market Historical Value (2017-2023)
3.2 Europe Viral Vector Manufacturing Market Forecast Value (2024-2032)
4 Europe Viral Vector Manufacturing Market Landscape*
4.1 Europe Viral Vector Manufacturing: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Europe Viral Vector Manufacturing: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
5 Europe Viral Vector Manufacturing Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Europe Viral Vector Manufacturing Market Segmentation (2017-2032)
6.1 Europe Viral Vector Manufacturing Market (2017-2032) by Type
6.1.1 Market Overview
6.1.2 Adenoviral Vectors
6.1.3 Adeno-Associated Viral (AAV) Vectors
6.1.4 Lentiviral Vectors
6.1.5 Retroviral Vectors
6.1.6 Others
6.2 Europe Viral Vector Manufacturing Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Gene Therapy
6.2.3 Cell Therapy
6.2.4 Vaccines
6.3 Europe Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
6.3.1 Market Overview
6.3.2 Oncological Disorders
6.3.3 Neurological Disorders
6.3.4 Metabolic Disorders
6.3.5 Immunological Disorders
6.3.6 Others
6.4 Europe Viral Vector Manufacturing Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Research Organizations
6.4.3 Biotech and Pharmaceutical Companies
6.4.4 Others
6.5 Europe Viral Vector Manufacturing Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 United Kingdom
6.5.3 Germany
6.5.4 France
6.5.5 Italy
6.5.6 Others
7 United Kingdom Viral Vector Manufacturing Market (2017-2032)
7.1 United Kingdom Viral Vector Manufacturing Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Adenoviral Vectors
7.1.3 Adeno-Associated Viral (AAV) Vectors
7.1.4 Lentiviral Vectors
7.1.5 Retroviral Vectors
7.1.6 Others
7.2 United Kingdom Viral Vector Manufacturing Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Gene Therapy
7.2.3 Cell Therapy
7.2.4 Vaccines
7.3 United Kingdom Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
7.3.1 Market Overview
7.3.2 Oncological Disorders
7.3.3 Neurological Disorders
7.3.4 Metabolic Disorders
7.3.5 Immunological Disorders
7.3.6 Others
7.4 United Kingdom Viral Vector Manufacturing Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Research Organizations
7.4.3 Biotech and Pharmaceutical Companies
7.4.4 Others
8 Germany Viral Vector Manufacturing Market (2017-2032)
8.1 Germany Viral Vector Manufacturing Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Adenoviral Vectors
8.1.3 Adeno-Associated Viral (AAV) Vectors
8.1.4 Lentiviral Vectors
8.1.5 Retroviral Vectors
8.1.6 Others
8.2 Germany Viral Vector Manufacturing Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Gene Therapy
8.2.3 Cell Therapy
8.2.4 Vaccines
8.3 Germany Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
8.3.1 Market Overview
8.3.2 Oncological Disorders
8.3.3 Neurological Disorders
8.3.4 Metabolic Disorders
8.3.5 Immunological Disorders
8.3.6 Others
8.4 Germany Viral Vector Manufacturing Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Research Organizations
8.4.3 Biotech and Pharmaceutical Companies
8.4.4 Others
9 France Viral Vector Manufacturing Market (2017-2032)
9.1 France Viral Vector Manufacturing Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Adenoviral Vectors
9.1.3 Adeno-Associated Viral (AAV) Vectors
9.1.4 Lentiviral Vectors
9.1.5 Retroviral Vectors
9.1.6 Others
9.2 France Viral Vector Manufacturing Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Gene Therapy
9.2.3 Cell Therapy
9.2.4 Vaccines
9.3 France Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
9.3.1 Market Overview
9.3.2 Oncological Disorders
9.3.3 Neurological Disorders
9.3.4 Metabolic Disorders
9.3.5 Immunological Disorders
9.3.6 Others
9.4 France Viral Vector Manufacturing Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Research Organizations
9.4.3 Biotech and Pharmaceutical Companies
9.4.4 Others
10 Italy Viral Vector Manufacturing Market (2017-2032)
10.1 Italy Viral Vector Manufacturing Market (2017-2032) by Type
10.1.1 Market Overview
10.1.2 Adenoviral Vectors
10.1.3 Adeno-Associated Viral (AAV) Vectors
10.1.4 Lentiviral Vectors
10.1.5 Retroviral Vectors
10.1.6 Others
10.2 Italy Viral Vector Manufacturing Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Gene Therapy
10.2.3 Cell Therapy
10.2.4 Vaccines
10.3 Italy Viral Vector Manufacturing Market (2017-2032) by Therapeutic Area
10.3.1 Market Overview
10.3.2 Oncological Disorders
10.3.3 Neurological Disorders
10.3.4 Metabolic Disorders
10.3.5 Immunological Disorders
10.3.6 Others
10.4 Italy Viral Vector Manufacturing Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Research Organizations
10.4.3 Biotech and Pharmaceutical Companies
10.4.4 Others
11 Regulatory Framework
12 Funding and Investment Analysis
12.1 Analysis by Funding Instances
12.2 Analysis by Type of Funding
12.3 Analysis by Funding Amount
12.4 Analysis by Leading Players
12.5 Analysis by Leading Investors
12.6 Analysis by Geography
13 Partnership and Collaborations Analysis
13.1 Analysis by Partnership Instances
13.2 Analysis by Type of Partnership
13.3 Analysis by Leading Players
13.4 Analysis by Geography
14 Supplier Landscape
14.1 Market Share by Top 5 Companies
14.2 Lonza Group AG
14.2.1 Financial Analysis
14.2.2 Product Portfolio
14.2.3 Demographic Reach and Achievements
14.2.4 Mergers and Acquisitions
14.2.5 Certifications
14.3 Merck KGaA
14.3.1 Financial Analysis
14.3.2 Product Portfolio
14.3.3 Demographic Reach and Achievements
14.3.4 Mergers and Acquisitions
14.3.5 Certifications
14.4 Oxford Biomedica
14.4.1 Financial Analysis
14.4.2 Product Portfolio
14.4.3 Demographic Reach and Achievements
14.4.4 Mergers and Acquisitions
14.4.5 Certifications
14.5 Novartis AG
14.5.1 Financial Analysis
14.5.2 Product Portfolio
14.5.3 Demographic Reach and Achievements
14.5.4 Mergers and Acquisitions
14.5.5 Certifications
14.6 Sartorius AG
14.6.1 Financial Analysis
14.6.2 Product Portfolio
14.6.3 Demographic Reach and Achievements
14.6.4 Mergers and Acquisitions
14.6.5 Certifications
14.7 SIRON Biotech
14.7.1 Financial Analysis
14.7.2 Product Portfolio
14.7.3 Demographic Reach and Achievements
14.7.4 Mergers and Acquisitions
14.7.5 Certifications
14.8 PlasmidFactory GmbH
14.8.1 Financial Analysis
14.8.2 Product Portfolio
14.8.3 Demographic Reach and Achievements
14.8.4 Mergers and Acquisitions
14.8.5 Certifications
14.9 Kaneka Eurogentec S.A.
14.9.1 Financial Analysis
14.9.2 Product Portfolio
14.9.3 Demographic Reach and Achievements
14.9.4 Mergers and Acquisitions
14.9.5 Certifications
14.10 Advanced BioScience Laboratories, Inc.
14.10.1 Financial Analysis
14.10.2 Product Portfolio
14.10.3 Demographic
14.10.4 Mergers and Acquisitions
14.10.5 Certifications
14.11 F. Hoffmann-La Roche AG
14.11.1 Financial Analysis
14.11.2 Product Portfolio
14.11.3 Demographic Reach and Achievements
14.11.4 Mergers and Acquisitions
14.11.5 Certifications
15 Europe Viral Vector Manufacturing Market – Distribution Model (Additional Insight)
15.1 Overview
15.2 Potential Distributors
15.3 Key Parameters for Distribution Partner Assessment
16 Key Opinion Leaders (KOL) Insights (Additional Insight)
17 Company Competitiveness Analysis (Additional Insight)
17.1 Very Small Companies
17.2 Small Companies
17.3 Mid-Sized Companies
17.4 Large Companies
17.5 Very Large Companies
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
18.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Europe viral vector manufacturing market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 19.74% during the forecast period of 2024-2032 and is likely to reach a market value of USD 13.5 billion by 2032.
The increasing focus on gene therapy and vaccine development is fuelling the demand for the market.
One of the significant trends in the market is the rise in strategic partnerships between the leading biotechnology companies and contract development and manufacturing organizations (CDMOs). In December 2023 , Oxford Biomedica entered into an agreement to acquire ABL Europe S.A.S. from Institut Mérieux SA. The acquisition will strengthen the company’s position as the leading cell and gene therapy CDMO.
Based on the type, the market is segmented into adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, and retroviral vectors, among others.
By therapeutic area, the market is divided into oncological disorders, neurological disorders, metabolic disorders, and immunological disorders, among others.
End users of the market are research organizations, biotech, and pharmaceutical companies, among others.
Major applications of viral vector manufacturing include gene therapy, cell therapy, and vaccines.
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy, among others.
The key players in the market are Lonza Group AG, Merck KGaA, Oxford Biomedica, Novartis AG, Sartorius AG, SIRON Biotech, PlasmidFactory GmbH, Kaneka Eurogentec S.A., Advanced BioScience Laboratories, Inc., and F. Hoffmann-La Roche AG.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER